Clinical Trials Directory

Trials / Completed

CompletedNCT04728802

Proxalutamide Treatment for Hospitalized COVID-19 Patients

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
645 (actual)
Sponsor
Applied Biology, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for hospitalized COVID-19 male and female patients.

Conditions

Interventions

TypeNameDescription
DRUGProxalutamideProxalutamide 300mg q.d
DRUGPlaceboPlacebo pill

Timeline

Start date
2021-02-01
Primary completion
2021-04-15
Completion
2021-04-15
First posted
2021-01-28
Last updated
2021-06-24
Results posted
2021-06-23

Locations

8 sites across 1 country: Brazil

Source: ClinicalTrials.gov record NCT04728802. Inclusion in this directory is not an endorsement.